{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immediate+Release+%28IR%29+Formulation&page=2", "query": { "intervention": "Immediate Release (IR) Formulation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 59, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immediate+Release+%28IR%29+Formulation&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immediate+Release+%28IR%29+Formulation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-30T09:19:51.805Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01100060", "title": "A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malaria Prophylaxis" ], "interventions": [ { "name": "azithromycin (AZ) microsphere", "type": "DRUG" }, { "name": "test chloroquine (CQ) formulation", "type": "DRUG" }, { "name": "azithromycin (AZ)", "type": "DRUG" }, { "name": "chloroquine (CQ)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 40, "start_date": "2010-04", "completion_date": "2010-06", "has_results": false, "last_update_posted_date": "2010-08-25", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01100060" }, { "nct_id": "NCT00364533", "title": "A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthroplasty" ], "interventions": [ { "name": "Tapentadol IR (CG5503)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Oxycodone HCL IR", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 367, "start_date": "2006-10", "completion_date": "2007-12", "has_results": true, "last_update_posted_date": "2014-04-21", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 45, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Sheffield", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Fort Smith", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00364533" }, { "nct_id": "NCT06708611", "title": "A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "torsemide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sarfez Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2025-01-15", "completion_date": "2025-03-25", "has_results": false, "last_update_posted_date": "2026-04-27", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06708611" }, { "nct_id": "NCT05889273", "title": "ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism Spectrum Disorder" ], "interventions": [ { "name": "ML-004 (IR)/(ER) tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MapLight Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "46 Years", "sex": "ALL", "summary": "12 Years to 46 Years" }, "enrollment_count": 120, "start_date": "2023-06-01", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 18, "location_summary": "Dothan, Alabama • Phoenix, Arizona • Glendale, California + 15 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Glendale", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Rafael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05889273" }, { "nct_id": "NCT07240116", "title": "Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Miricorilant Treatment A", "type": "DRUG" }, { "name": "Miricorilant Treatment B", "type": "DRUG" }, { "name": "Miricorilant Treatment C", "type": "DRUG" }, { "name": "Miricorilant Treatment D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 18, "start_date": "2025-09-11", "completion_date": "2026-03-03", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07240116" }, { "nct_id": "NCT01332513", "title": "An Open Label, Randomised, Repeat Dose Study to Assess the Pharmacokinetic Performance of Five Ezogabine/Retigabine Modified Release (MR) Formulations at Steady State Compared to the Immediate Release (IR) Formulation.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Investigational Medicinal Product (MR1)", "type": "DRUG" }, { "name": "Investigational Medicinal Product (MR2)", "type": "DRUG" }, { "name": "Investigational Medicinal Product (MR3)", "type": "DRUG" }, { "name": "Investigational Medicinal Product (MR4)", "type": "DRUG" }, { "name": "Investigational Medicinal Product (MR5)", "type": "DRUG" }, { "name": "Investigational Medicinal Product (IR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 36, "start_date": "2011-02-10", "completion_date": "2011-05-23", "has_results": false, "last_update_posted_date": "2018-06-19", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332513" }, { "nct_id": "NCT00914641", "title": "Bioavailability Study Comparing Modified Release To Immediate Release Apixaban Tablets In Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Thrombosis" ], "interventions": [ { "name": "Apixaban IR", "type": "DRUG" }, { "name": "Apixaban MR1", "type": "DRUG" }, { "name": "Apixaban MR2", "type": "DRUG" }, { "name": "Apixaban MR3", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 16, "start_date": "2009-06", "completion_date": "2009-08", "has_results": false, "last_update_posted_date": "2009-08-25", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT00914641" }, { "nct_id": "NCT00256854", "title": "Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Restless Legs Syndrome", "Restless Legs Syndrome (RLS)" ], "interventions": [ { "name": "Ropinirole IR 1 mg", "type": "DRUG" }, { "name": "Ropinirole IR 2 mg", "type": "DRUG" }, { "name": "Ropinirole IR 1 mg Placebo", "type": "DRUG" }, { "name": "Ropinirole IR 2 mg Placebo", "type": "DRUG" }, { "name": "Ropinirole CR 2 mg", "type": "DRUG" }, { "name": "Ropinirole CR 3 mg", "type": "DRUG" }, { "name": "Ropinirole CR 2 mg Placebo", "type": "DRUG" }, { "name": "Ropinirole CR 3 mg Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 135, "start_date": "2005-11-14", "completion_date": "2006-09-21", "has_results": true, "last_update_posted_date": "2019-03-15", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 30, "location_summary": "Laguna Hills, California • Oxnard, California • Pasadena, California + 27 more", "locations": [ { "city": "Laguna Hills", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Reseda", "state": "California" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00256854" }, { "nct_id": "NCT03670953", "title": "A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson's Disease (Disorder)" ], "interventions": [ { "name": "IR CD-LD", "type": "DRUG" }, { "name": "IPX203 ER CD-LD", "type": "DRUG" }, { "name": "Placebo Matching IPX203", "type": "OTHER" }, { "name": "Placebo Matching IR CD-LD", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Impax Laboratories, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 630, "start_date": "2018-11-06", "completion_date": "2021-06-15", "has_results": true, "last_update_posted_date": "2023-02-09", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 56, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03670953" }, { "nct_id": "NCT04580797", "title": "Clinical Study to Evaluate Pharmacokinetics and Safety of PF-06700841 After Single and Multiple Oral Doses as Modified Release Formulations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "PF-06700841 IR", "type": "DRUG" }, { "name": "PF-06700841 MR1", "type": "DRUG" }, { "name": "PF-06700841 MR2", "type": "DRUG" }, { "name": "PF-06700841 MR3", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2020-10-02", "completion_date": "2021-01-11", "has_results": false, "last_update_posted_date": "2021-03-08", "last_synced_at": "2026-09-30T09:19:51.805Z", "location_count": 2, "location_summary": "Coral Gables, Florida • Miami, Florida", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04580797" } ] }